News

Eveliqure Biotechnologies GmbH announced the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject…

23 Sep'20

Proper folding of extremely long chromosomal DNA molecules is crucial for the correct functioning of the cell. Scientists from the Gerlich lab at IMBA…

21 Sep'20

The Vienna Covid-19 Detection Initiative (VCDI) is a collaborative, inter-institutional effort to combat the SARS-CoV-2 coronavirus. It draws from…

18 Sep'20

Valneva announced the retirement of its Chief Financial Officer, David Lawrence, at the end of 2020.

18 Sep'20

The Aligning Science Across Parkinson’s Initiative (ASAP) has awarded a grant to Sascha Martens’ group and scientists from the University of…

17 Sep'20

Eveliqure Biotechnologies GmbH announced the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID),…

17 Sep'20

CEBINA GmbH announced further positive results in its collaborative COVID-19 drug repurposing project, demonstrating that a common allergy nasal spray…

15 Sep'20

A new role for Casein Kinase-1 on RNF43 is identified – Study by Tadasuke Tsukiyama and IMBA – Institute of Molecular Biotechnology of the Austrian…

14 Sep'20

Valneva announced a vaccine partnership with the UK government for its inactivated COVID-19 vaccine, VLA2001.

09 Sep'20

Since 1947, the City of Vienna honours residents distinguished in a range of disciplines with the “Preis der Stadt Wien” awards for their life…

09 Sep'20

Valneva announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its…

08 Sep'20

Valneva announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553. The…

Eveliqure announces the initiation of a Phase 1 clinical study of its combined Shigella and ETEC vaccine candidate

Unraveling the genome in 3D-space

Vienna Covid-19 Detection Initiative (VCDI): a response to Covid-19 from the Vienna BioCenter

Valneva Announces Retirement of Chief Financial Officer David Lawrence

Investigating Parkinson’s through the lens of autophagy - ASAP grant for Sascha Martens

Eveliqure announces the award of a NIAID contract to finance Phase 2 clinical studies of its combined Shigella and ETEC vaccine candidate

CEBINA reports positive findings on the potency of azelastine, a widely used antihistamine, as anti-COVID-19 approach

The Wnt pathway gets even more complicated

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

City of Vienna honours Meinrad Busslinger

Valneva Announces New IXIARO® Supply Contract with the US Government worth up to $166 million

Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553